PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 127
- Registration Number
- NCT04428502
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT04427917
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 280
- Registration Number
- NCT04424303
- Locations
- 🇫🇷
Clinique de l Europe, Amiens, France
🇫🇷Hopital D'Estaing, Clermont Ferrand, France
🇫🇷Hopital Sud, Amiens, France
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
- Conditions
- Respiratory Tract Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14727
- Registration Number
- NCT04424316
- Locations
- 🇺🇸
Pocatello Women's Health Clinic, Pocatello, Idaho, United States
🇺🇸1st Choice Urgent Care, Pocatello, Idaho, United States
🇺🇸The Iowa Clinic, Ankeny, Iowa, United States
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT04413617
- Locations
- 🇧🇬
Independent Medical Diagnostic Laboratory Mediscan EOOD, Plovdiv, Bulgaria
🇧🇬MHAT Plovdiv AD, Plovdiv, Bulgaria
🇧🇬DCC Sveti Georgi EOOD, Plovdiv, Bulgaria
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04412252
- Locations
- 🇺🇸
LSUHSC-Shreveport, Shreveport, Louisiana, United States
🇺🇸Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46
- Conditions
- Healthy
- Interventions
- Biological: TA-46Other: Placebo
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT04410809
- Locations
- 🇳🇱
PRA, Groningen, Netherlands
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 974
- Registration Number
- NCT04408794
- Locations
- 🇺🇸
Ki Health Partners, LLC dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Boston Clinical Trials, Boston, Massachusetts, United States
🇺🇸Pharmacology Research Institute, Los Alamitos, California, United States
PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT04403776
- Locations
- 🇨🇳
Shuguang Hospital Affiliated to Shanghai University of TCM/Phase I Unit, Shanghai, China
Actigraphy Improvement With Voxelotor (ActIVe) Study
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT04400487
- Locations
- 🇺🇸
The Children's Hospital at Montefiore, Bronx, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States